Brief: Royalty Pharma Acquires Royalty Interest In Nuvalent’S Neladalkib And Zidesamtinib For Up To $315 Million

Royalty Pharma

16/12/2025 12:18

Dec 16 (Reuters) - Royalty Pharma PLC RPRX.O:

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT’S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION

ROYALTY PHARMA  - ROYALTY DURATION FOR BOTH THERAPIES EXTENDS THROUGH 2041 TO 2042

ROYALTY PHARMA  - BUYS LOW-SINGLE DIGIT ROYALTY ON NELADALKIB AND ZIDESAMTINIB

Source text: ID:nGNX3bzBw1

Further company coverage: RPRX.O

 ((Reuters.Briefs@thomsonreuters.com;))